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 i g  h  l  i  g  h  t  s
LPS-induced  sepsis  leads  to long-lasting  changes  in affective  behaviours.
Chronic  fluoxetine  treatment  following  recovery  from  sepsis  attenuates  such  changes  in  affective  behaviours.
Chronic  fluoxetine  treatment  also  attenuates  post-septic  decreases  in  cell  proliferation  in  the  dentate  gyrus,  decreased  expression  of EGR1  in  the  CA1
and increased  microglial  activation  in  the  hippocampus.
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a  b  s  t  r  a  c  t
It has  been  previously  demonstrated  that the induction  of  sepsis  in rodents  results  in persistent  impair-
ments  in affective  and  cognitive  domains.  In this  study  we have  examined  the impact  of  chronic  treatment
with  the  antidepressant  fluoxetine  on affective  behaviours  and  hippocampal  neuroinflammation  and
stem  cell  proliferation  in  animals  that have  previously  undergone  sepsis  induced  by peripheral  treat-
ment  with  lipopolysaccharide.  We  find  that  fluoxetine  significantly  attenuates  post-septic  increases  in
behavioural  despair  and  motivated  exploration,  whilst  also  reversing  the  effects  of  previous  sepsis  oneywords:
epsis
luoxetine
euoinflammation
GR1
epression
activated  microglia  and  stem  cell  proliferation.  These  results  indicate  that  conventional  antidepressants
may  be  effective  in  the  management  of  mood  disorders  in  survivors  of sepsis.
© 2015  Elsevier  B.V.  All  rights  reserved.rdU
It is increasingly recognised that survivors of sepsis may  experi-
nce a long-lasting syndrome of cognitive and behavioural changes
f uncertain aetiology that can significantly impact on quality of life
1]. Similar changes in cognitive and behavioural domains can be
escribed in animal models of sepsis-survival, indicating that such
pproaches may  be useful in understanding mechanisms and fac-
ors that shape post-septic impairments [2,3]. We  have recently
escribed that in a mouse model in which sepsis is induced by
 sub-lethal treatment with lipopolysaccharide (LPS) there are
ong-lasting changes in affective domains, including increased
ehavioural despair and increases in anxiety-like behaviours [4].
n post-septic animals there is also decreased cellular prolifera-
ion in the dentate gyrus, altered hippocampal expression of the
∗ Corresponding author at: Maynooth University Department of Psy-
hology, National University of Ireland, Maynooth, County Kildare, Ireland.
ax: +353 17084767.
E-mail address: andrew.coogan@nuim.ie (A.N. Coogan).
ttp://dx.doi.org/10.1016/j.bbr.2015.10.011
166-4328/© 2015 Elsevier B.V. All rights reserved.neural plasticity-related immediate early genes EGR1 and ARC, and
evidence of increased and long-lasting neuroinflammation [4].
There are emerging links between neuroinflammation and
affective disorders such as major depression that suggest that neu-
roimmune factors may  be therapeutic targets in the treatment of
mood disorders [5,6]. The selective serotonin reuptake inhibitor
fluoxetine, a commonly used anti-depressant, has been described
to exert anti-neuroinflammatory properties [7–9], as well as exert-
ing effects on neurogenesis and neural plasticity [10,11]. Given the
need to identify potential therapeutic strategies for the allevia-
tion of post-septic symptoms, in the current study we examined
whether chronic fluoxetine treatment following recovery from LPS-
induced sepsis could attenuate some of the previously described
affective and neurochemical changes observed in the mouse.
For the purpose of all experiments male C57BL/6 mice (Charles
River, Kent, UK; N = 41) were used. Animals were aged 8 weeks
at the start of the experimental procedures. Animals were group
housed in a 12:12 light:dark cycle for 2 weeks prior to LPS
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Fig. 1. Schematic illustrating the experimental design utilised in this study. Half of the study cohort received i.p. LPS (5 mg/kg), with the other half receiving vehicle. After 7
days  the animals were commenced on fluoxetine treatment (10 mg/kg/day via drinking water; N = 10 or 11 for previously LPS-treated animals, N = 10 for previously vehicle
t als, N
a aze (
t 0 mg/k
a
t
r
l
r
p
N
D
m
t
L
w
t
B
t
w
t
b
b
r
s
o
t
a
s
o
m
b
t
w
t
fi
m
t
s
f
o
s
f
a
b
a
fi
p
t
m
M
s
ireated  animals) or control drinking water (N = 10 for previously LPS-treated anim
nimals were tested on the novel object exploration task (NOE), the elevated plus m
hen  discontinued for 7 days. All animals then received an i.p. treatment of BrdU (5
dministration. Food and water were available ad libitum and
emperature was 21 ± 1 ◦C and humidity was 50 ± 10%. Animals
emained housed in groups of 2–4 in polypropylene cages (33 cm
ong × 15 cm wide × 13 cm high) with wood chip bedding and envi-
onmental enrichment (shredded paper and cardboard tubes). All
rocedures were approved by the Research Ethics Committee,
ational University of Ireland Maynooth, and were licensed by the
epartment of Health and Children, Ireland under statutory instru-
ent No. 543 of 2012 and the European directive 2010/63/EU.
The experimental regime employed is represented in Fig. 1. For
he induction of sepsis, animals were given a single i.p. treatment of
PS (5 mg/kg; serotype 0111.B4, Sigma Ireland) or control animals
ere treated with vehicle sterile saline. One week after LPS/vehicle
reatment, animals were treated with fluoxetine (10 mg/kg, Tocris
ioscience, UK) in standard drinking water, or just water for con-
rol. Fresh fluoxetine was given every second day; animals and
ater were weighed to ensure the correct dosage was  main-
ained. Animals were given fluoxetine or vehicle for 28 days
efore behavioural testing began and throughout the duration of
ehavioural testing. Animals were tested on the novel object explo-
ation task followed by the elevated plus maze and then the tail
uspension test. All behavioural tests were carried out as previ-
usly described, and the selection of behavioural tests was  made on
he basis of results from our previous study regarding post-septic
ffective and cognitive changes in the mouse [4]. Briefly, for the tail
uspension test mice were attached to a support raised to a height
f 121 cm using tape placed 1 cm from the tip of their tales for six
inutes. Mice were suspended for six minutes each, with immo-
ility (complete absence of movement) being recorded throughout
he entire six minutes. For the novel object exploration task animals
ere first habituated to an arena of 50 cm and then underwent 5
rials lasting two minutes being habituated to two  objects. On the
fth trial, one familiar object was replaced with a novel object. Ani-
als were measured on their time touching, and number of nose
ouches for each object. As such we primarily use this task as a mea-
ure of exploratory motivation, but also calculate preference ratios
or exploration of the novel object in the probe trial as a measure
f working memory. For the elevated plus maze, the maze con-
isted of a centre area of diameter 13.5 cm at a height of 20 cm,
rom which four arms extended of length 34.5 cm,  width 5 cm.  Two
rms were open without walls, while the other two were enclosed
y high walls. Entrance to an arm was counted where all four of
n animals’ paws were within the arm. Animals underwent one
ve-minute testing session each.
To assess the rate of cellular proliferation in the hippocam-
us mice were injected i.p. with 50 mg/kg BrdU one week after
he conclusion of behavioural testing. 24 h later mice were ter-
inally anaesthetised with 0.1 ml  sodium pentobarbital (Euthatal,
erial Animal Health, UK) and perfused transcardially with 0.9%
aline, with brains fixed in 4% paraformaldehyde (Sigma Ireland)
n 0.1 M phosphate buffer (PB), pH 7.4 at 4 ◦C. Brains were then = 10 for previously vehicle treated animals). After twenty eight days of treatment
EPM) and the tail-suspension test (EPM). Treatment with fluoxetine or vehicle was
g) and were perfused 24 h later.
cryoprotected in 0.1 M PB containing 30% sucrose, frozen and
sectioned coronally at 30 m.  Immunohistochemistry for IBA1
(1:3000, rabbit polyclonal primary antibody, Wako, Denmark; 019-
19741), EGR1 (1:3000, rabbit polyclonal primary antibody, Santa
Cruz Biotechnology; sc-189) and BrdU (1:200, rat monoclonal pri-
mary antibody, AbD Serotec, Oxford, UK; MCA2060) was carried out
following a standard Avidin–Biotin Complex/Nickel DAB protocol
as previously described [4,12]. Photomicrographs of sections were
taken using a digital camera connected to an Olympus BX-51 light
microscope under constant light intensity. Morphology and num-
ber of active microglia (stages 3–5 of Kreutzberg [13]) stained with
IBA1 were assessed under 100× magnification within a pre-defined
area. EGR1 immunoreactivity was assessed by optical density with
ImageJ 1.43 (NIH, USA). BrdU immunopositive cells in the dentate
gyrus were counted by eye. All image assessment was  carried out
by an experimenter blind to the experimental manipulation.
Data from the behavioural experiments and neurochemical data
were assessed via a factorial multivariate analysis of variance
(MANOVA). The dependent variables for the behavioural data were
time spent immobile on the tail suspension test, time spent in open
arms on the elevated plus maze and touches to both objects on the
probe trial of the novel object exploration task. The factors were
prior LPS treatment or vehicle and fluoxetine treatment or vehi-
cle. For immunohistochemical data the dependent variables were
cells incorporating BrdU, optical density for EGR1 and the num-
ber of IBA1-positive microglia with activated-like morphology. For
post-hoc analysis Bonferroni corrections were applied. P < 0.05 was
considered statistically significant. All data are presented as means
and standard error of the mean.
As previous data from our laboratory had demonstrated that
LPS-induced sepsis was  associated with a persistent increase in
immobility in the tail suspension test, decreased object explo-
ration in the probe trial of a novel object exploration task and
decreased time spent in the open arms of the elevated plus maze,
we examined whether these post-sepsis-associated changes would
be ameliorated by chronic fluoxetine treatment (Fig. 2). MANOVA
results from the behavioural experiments indicate that there is a
statistically significant interaction between LPS treatment and sub-
sequent fluoxetine treatment, and that the magnitude of such an
effect is large (F3,37 = 20.43, P < 0.001, partial eta squared = 0.629).
There were also significant main effects of both LPS treatment
(F3,37 = 22.17, P < 0.001, partial eta squared = 0.65) and fluoxetine
treatment (F3,37 = 5.5, P < 0.01, partial eta squared = 0.32). Consid-
ering the outcomes of the individual behavioural tests, there were
statistically significant interactions between LPS treatment and flu-
oxetine treatment for the tail suspension test (F1,37 = 36.1, P < 0.001,
partial eta squared = 0.49) and the novel object exploration test
(F1,37 = 5.27, P < 0.05, partial eta squared = 0.12), but not the elevated
plus maze (F1,37 = 1.88, P = 0.163). For the novel object exploration
test, there were no significant effects on the preference for explo-
ration of the novel object versus the familiar object, as has been
114 S.T. Anderson et al. / Behavioural Brain Research 297 (2016) 112–115
Fig. 2. Previous LPS-induced sepsis increased immobility on the tail suspension test (A), decreased time spent in open arms on the elevated plus maze (B) and decreased
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touches to objects in the probe trial of the novel object exploration task (C). Fluoxet
est  and the novel object recognition task, as indicated by LPS × fluoxetine interactio
rom  LPS + Veh group where N = 11.
reviously reported [4]. These results indicate that chronic fluoxe-
ine treatment after the induction of sepsis significantly attenuates
ehavioural changes observed on the tail suspension test and the
ovel object exploration task.
Analysis of the immunohistochemical data likewise indi-
ates that post-septic treatment with fluoxetine attenuates some
ffects previously described in post-septic animals [4]. Consider-
ng BrdU incorporation in the dentate gyrus, EGR1 expression in
he CA1 and hippocampal expression of IBA1 (Fig. 3), MANOVA
emonstrates a significant, large magnitude interaction between
PS treatment and fluoxetine treatment (F3,37 = 27.1, P < 0.001,
artial eta squared = 0.699). There were also significant main
ffects of both LPS treatment (F3,37 = 37.9, P < 0.001, partial eta
quared = 0.77) and fluoxetine treatment (F3,37 = 33.74, P < 0.001,
artial eta squared = 0.75). Analysis of the separate dependent
ariables shows significant LPS × fluoxetine interactions for BrdU
F1,37 = 23.8, P < 0.001, partial eta squared = 0.391), EGR1 (F1,37 = 6.3,
 < 0.05, partial eta squared = 0.146) and IBA1 (F1,37 = 42.9, P < 0.001,
artial eta squared = 0.537).
ig. 3. Previous LPS-induced sepsis resulted in significantly less BrdU-immunoreactive cel
BA-1-immunopositive activated microglia across the hippocampus (C). Subsequent fluox
hree  antigens, as indicated by LPS × fluoxetine interactions. Scale bar in the photomicrogatment significantly attenuated the effects of previous sepsis in the tail suspension
e horizontal lines represent the group means. N = 10 for each treatment group apart
These results indicate that in murine survivors of LPS-induced
sepsis that chronic fluoxetine treatment can attenuate both affec-
tive behavioural and hippocampal neurochemical changes. Of
particular interest is that fluoxetine treatment was  not adminis-
tered until 7 days after LPS treatment, and as such did not impact
on post-septic effects by modulating sepsis severity. Previous stud-
ies have shown that in animal models strategies that target the
acute phase of sepsis lead to diminution of post-septic cognitive
and behavioural effects [4,14–16]. However, for the management
of post-septic impairments in patients it will be important to iden-
tify strategies that may  be effective in survivors, aside from the
obvious need to identify therapeutics that reduce sepsis severity
and increase survival. From this point of view, it is encouraging
that a commonly prescribed antidepressant, fluoxetine, appears
to be effective in this pre-clinical study at ameliorating post-
septic effects in the mouse. Interestingly, a previous study reported
that acute treatment with the antidepressant imipramine reversed
depressive-symptoms in rats 10 days following caecal ligation and
perforation-induced sepsis [17], a finding which is similar to that
ls in the dentate gyrus (A), less EGR1-immunoreactivity in the CA1 (B) and increased
etine treatment significantly attenuates these changes in post-septic animals in all
raphs = 100 m.  N = 10 or N = 11 for each group.
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stress-induced depressive-like behavior and suppressed neurogenesis, Mol.
Psychiatry 19 (6) (2014) 699–709.S.T. Anderson et al. / Behavioura
eported for acute treatment with fluoxetine in LPS-induced sepsis
urvivor mice [4]. However, no previous study has addressed the
fficacy of post-septic chronic anti-depressant treatment, a treat-
ent modality that is likely to be of greater translatable significance
nd predictive validity than acute treatments. Further, no previ-
us study has examined the impact of antidepressant treatment on
eurochemical processes that may  underpin affective changes in
epsis-survivor animals. One previous study indicated that post-
eptic chronic treatment with anti-high mobility group box 1
ntibodies also attenuated cognitive impairment and hippocampal
endritic spine loss [18], indicating that there may  be numerous
echanisms through which post-septic changes in behaviour and
ognition may  be targeted.
The aetiology of post-septic encephalopathy is likely to be
omplex, involving factors such as impaired blood-brain barrier
unction, oxidative stress, neuroinflammation, decreased neural
lasticity and altered EEG rhythms [19]. These mechanisms are
ikely to be highly interconnected; for example, sepsis-induced
ctivation of microglia may  underlie concomitant synaptic dys-
unction and increased oxidative damage [20,21]. It is interesting
o note that in the present study that the fluoxetine-induced atten-
ation of affective behaviours was found in parallel with decreased
icroglial activation and rescue of cellular proliferation in the
entate gyrus and EGR1 levels in the CA1. Previous studies have
ndicated an anti-neuroinflammatory role for fluoxetine via upreg-
lation of anti-inflammatory mediators such as interleukin 4 [9]
nd an effect in downregulating oxidative stress [22]. Given that
icroglia may  be important regulators of neurogenesis in mod-
ls of affective disorders [23], there may  be a direct link between
icroglial activation and altered rates of hippocampal stem cell
roliferation following sepsis that is acted on by fluoxetine. Inter-
stingly fluoxetine has been shown to be effective in restoring rates
f neural stem cell proliferation in a model of depression involving
re-natal LPS treatment [24].
There are a number of important caveats and limitations
f the current study: we did not assess profiles of pro- and
nti-inflammatory cytokines and important mediators of neuroin-
ammation, and as such we lack mechanistic insight into how
uoxetine may  exert its seemingly beneficial actions in post-septic
ice; further, we did not examine factors known to regulate neu-
ogeneis, such as brain-derived neurotrophic factor. Future studies
hould address these questions. The results of the current study also
aise a number of further questions: would other anti-depressants
e effective in ameliorating post-septic affective changes; would
uoxetine be effective in the treatment of sepsis survivor patients
ho display mood disorders (and/or cognitive impairments); is
here a time-window in which post-septic treatment may  only be
ffective; is there utility in the combination of fluoxetine (or other
ntidepressants) with drugs such as cecoxilib or minocycline that
irectly target neuroinflammation? There is a clear need for fur-
her pre-clinical and clinical studies to guide the future treatment
f survivors of sepsis.
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